CMS (00867.HK), through its wholly-owned subsidiary, has signed a Collaboration Agreement dated 5 December 2019 with the University of Cambridge and AstraZeneca UK Limited (“AstraZeneca”). Through the collaboration, the Company will invest in the UK biotech and life sciences sectors over the next five years, with support from the established networks and relationships of AstraZeneca and Cambridge Judge Business School (“CJBS”).
The investment of CMS may provide it with the opportunity to secure rights to the products developed by the invested companies in the future for Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).
Since 2015, AstraZeneca has played a role in mentoring biotech and life sciences researchers and innovators and has partnered with CJBS on various programmes to promote enterprise and support entrepreneurship amongst life sciences researchers and students.
Through the Collaboration Agreement, CMS, AstraZeneca and CJBS demonstrate a common objective of strengthening the pipeline of opportunities in biotech and life sciences, more specifically in the areas of therapeutics, diagnostics, devices and digital health, thus providing the invested companies with greater access to international markets in particular Greater China.